The role of gemcitabine alone and in combination in the treatment of pancreatic cancer

Anti-Cancer Drugs

Volumn 11, Issue 10, 2000, Pages 771-786

  Oettle, Helmut ^a   Arnold, Dirk ^a   Hempel, Christine ^a   Riess, Hanno ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Combination treatment; Gemcitabine; Pancreatic cancer

Indexed keywords

DOCETAXEL; FLUOROURACIL; GEMCITABINE; NUCLEOSIDE ANALOG; PACLITAXEL; RALTITREXED;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; GASTROINTESTINAL TUMOR; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS;

EID: 0033638288     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200011000-00001     Document Type: Review

References (116)

1. Palliative and supportive care of patients with pancreatic cancer
2. Cancer of the pancreas
3. Cancer statistics
4. Treatment of advanced and metastatic pancreatic cancer
5. Cancer of the pancreas
6. Chemotherapy in the treatment of cancer of the pancreas
7. Possibilities of palliation in pancreatic cancer
8. Practical recommendations for the management of adenocarcinoma of the pancreas
9. Current chemotherapeutic possibilities in pancreaticobiliary cancer
10. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
11. Chemotherapy of gastrointestinal cancer
12. Continuous 5-fluorouracil infusion in carcinoma of the pancreas
13. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial
14. Chemotherapy for pancreatic carcinoma
15. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxombicin vs fluorouracil, doxorubicin and mitomycin
16. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM), with 5-fluorouracil, streptozocin and mitomycin (FSM)
17. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluation of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin
18. A phase III comparison trial of streptozocin, mitomycin and fluorouracil with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma
19. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer
20. A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas
21. Phase II trial of docetaxel (taxotere) as first-line chemotherapy in patients with metastatic pancreatic cancer. A Japanese co-operative study
22. Treatment of advanced pancreatic cancer (APC) with docetaxel (D): A multicenter phase II study
23. Phase II study of docetaxel as first-line chemotherapy in metastatic adenocarcinoma of the pancreas
24. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas
25. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer
26. A phase II study of Temozolomide in advanced untreated pancreatic cancer
27. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenoma of the pancreas
28. Phase II study of gemcitabine in patients with advanced pancreatic cancer
29. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
30. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
31. An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma
32. Phase II study of gemcitabine as locoregional treatment of advanced pancreatic cancer
33. Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2',2' difluorodeoxycytidine
34. A phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
35. Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): A phase II study in advanced pancreatic cancer (APC)
36. Gemcitabine and continuous infusion 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer
37. Phase I-II study of gemcitabine (GEM) and weekly 48 hour continuous infusion (CI) high dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC)
38. Phase II study of gemcitabine (Cr) and continuous intravenous infusion (CIV) 5-fluourouracil (5-FI) in advanced pancreatic cancer (PC). A University of Chicago Phase II Consortium Study
39. High-dose fluorouracil (FU) 24-H-infusion with gemcitabine (GEM): Tolerable and efficient in palliative outpatient treatment of pancreatic cancer
40. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
41. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Co-operative Group Study (E 3296)
42. Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer
43. Phase II trial of the use of gemcitabine (G) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and biliary tract (ABTC) adenocarcinoma
44. Weekly gemcitabine (GEM) and 5-fluorouracil (5-FU) in pancreatic carcinoma. Phase I-II study
45. Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
46. A phase II trial of gencitabine in combination with 5-fluorouracil (24 hr) and folinic acid in patients with chemonaive advanced pancreatic cancer
47. A phase II study of gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer
48. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5-FU bolus and infusion, and gemcitabine (FOLFUGEM Regimen)
49. Phase I/II study in advanced pancreatic adenocarcinoma (APA) and carcinoma of unknown primary (CUP): A combination of leucovorin (LV), 5-FU bolus and infusion, gemcitabine (GEM) and oxaliplatine (L-OHP) (FOLFU GEMOX REGIMEN)
50. A phase I study of gemcitabine (GEM) in combination, with 5 days 5 fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct
51. Phase II trial of gemcitabine (GEM), 5-fluorouracil and leucovorin (LV) in advanced pancreatic cancer (APC)
52. A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing of administration of gemcitabine (G) and folinic acid (FA)/fluorouracil (FU) in advanced pancreatic cancer (APC)
53. Phase I-II study of gemcitabine (GEM) in combination with 24 hours continuous infusion (CI) of 5-fluorouracil (5-FU) and L-leucovorin (LV) in patients (pts) with advanced pancreatic carcinoma (APC)
54. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer: Results of a phase I trial
55. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic cancer
56. Synergistic interaction between cisplatin and gemcitabine in vitro
57. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer: Final results of a phase II study
58. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
59. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): A phase II multicenter study of the Southern Italy Oncology Group
60. Combination therapy with Oxaliplatin+Gemcitabine in advanced pancreatic cancer
61. Treatment of advanced pancreatic carcinoma with 5-FU leucovorin, interferon-alpha-2b and cisplatin
62. Docetaxel delivers new management opportunities for gastrointestinal carcinomas
63. Docetaxel a potentially active agent for patients with pancreatic adenocarcinoma
64. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with a advanced pancreatic cancer: A multicenter phase II study
65. A phase I/II study of gemcitabine (G) and Taxotere (T) in patients with unresectable pancreatic carcinoma
66. Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer
67. Final results of a phase I study of weekly gemcitabine and docetaxel in pancreatic cancer and preliminary results of a phase II study
68. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
69. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: A multicenter phase II study
70. Docetaxel chemotherapy for pancreatic cancer: Do results support certainty?
71. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study
72. Dose-finding study of gemcitabine and epirubicin in patients with advanced pancreatic cancer
73. Phase II trials of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer
74. Preliminary results of gemzar+mitomycin in treatment of advanced pancreatic cancer
75. Gemzar (GEM)+Mitomycin C (MMC) in patients with advanced pancreatic cancer (APC)
76. Locoregional systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers
77. Phase II trial of high dose continuous octreotide infusion (hdcoi) and gemcitabine (gm) in advanced pancreatic cancer (pc)
78. A phase I/II trial of SMS 201-995 pa LAR (SMS pa LAR) and gemcitabine in patients with advanced pancreatic cancer
79. Gemcitabine (GEM) and tamoxifen (TAX) in patients with advanced pancreatic cancer (APC). Impact on quality of life of an innovative association
80. Phase 1B study of concurrent administration of marimastat and gemcitabine in nonresectable pancreatic cancer
81. Phase Ib study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer
82. A phase 2 trial of capecitabine in advanced or metastatic pancreatic cancer
83. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial
84. Front-line treatment of pancreatic carcinoma with gemcitabine in combination with irinotecan (CPT-11): Preliminary results of a multicentre phase II study
85. Multicenter phase II trial of first-line irinotecan and gemcitabine (Iriongem) in patients with locally advanced or metastatic pancreatic cancer (PC)
86. PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine): A new combination in advanced pancreatic adenocarcinoma. Phase II study
87. Significant improvement of response rate and survival with cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEF-G regimen) in metastatic pancreatic cancer
88. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
89. Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil
90. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: A phase II study of the Puget Sound Oncology Consortium (PSOC-703)
91. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: Results of a feasibility study
92. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma
93. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluoro-uracil, leucovorin and cisplatin
94. A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy
95. Radiosensitisation of human solid tumour cell lines by gemcitabine
96. Phase I trial of concurrent gemcitabine (GEM) infusional 5-fluourouracil (FU) and radiation therapy (RT) in patients with localized unresectable pancreatic adenocarcinoma
97. A phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer
98. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma
99. Phase I study of concurrent radiation and twice weekly gemcitabine in advanced/metastatic pancreatic cancer
100. Phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
101. Gemcitabine (G) in combination radiationtherapy (RT) in stage III-IV pancreatic cancer: First results of a current Phase I study
102. A phase II study of hypofractionated radiotherapy in combination with Gemcitabine in the palliative treatment of advanced pancreatic carcinoma
103. Chemoradiation therapy with gemcitabine (GEM) in advanced pancreatic cancer (APC)
104. Radiochemotherapy including gemcitabine and 5-fluourouracil for treatment of locally advanced pancreatic cancer
105. Pancreatic carcinoma: Simultaneous radiochemotherapy with gemcitabine and cisplatin. A pilot study
106. Phase I trial of gemcitabine, cisplatin (CDDP) and external beam radiation therapy (EBRT) for pancreatic vancer
107. Locally advanced pancreatic carcinoma: Neoadjuvant radiochemotherapy (RCT) with 5-FU and mitomycin C
108. Feasibility and phase II study of combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas
109. Intra-arterial chemotherapy (iaCT) combined with radiation (RT) for advanced pancreatic cancer
110. Adjuvant combined modality therapy for resected high-risk adenocarcinoma of the pancreas using cisplatin (CDDP), 5-FU, and α-interferon (IFNγ) as radiosensitising agents: Update of a phase II trial
111. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic carcinoma
112. Inhibitors of angiogenesis enter phase III testing
113. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus mediated delivery of the herpes simplex virus thymidine kinase gene
114. A phase I trial of intratumoral injection of an E1B attenuated adenovirus, ONYX-O15, into unresectable carcinomas of the exocrine pancreas
115. Gemcitabine-Ad5CMVp53 combination treatment enhances the regression of human pancreatic tumours